The spectrum of nodular lymphocyte predominant Hodgkin lymphoma: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology.
Diagnostic workshop
Gene expression profiling
Immune microenvironment
Nodular lymphocyte predominant Hodgkin Lymphoma
T-cell/histiocyte-rich large B-cell lymphoma
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
13
02
2023
accepted:
24
04
2023
revised:
13
04
2023
medline:
30
10
2023
pubmed:
2
8
2023
entrez:
2
8
2023
Statut:
ppublish
Résumé
Session 4 of the 2021 European Association of Haematopathology/Society for Hematopathology Workshop focused on nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). First, the spectrum of immunophenotypic variations in NLPHL and the defining criteria for classic Hodgkin Lymphoma (CHL) were discussed. The added value of further immunophenotypic characterization of both tumor cells and microenvironment to support the differential diagnosis was presented. Next, unusual cases with combined growth patterns and evolution of morphological features over time were presented to explore the clinicopathological impact of presumed high-risk patterns. Based on a large collection of cases, the defining morphological, immunophenotypical, and gene expression features of T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) and THRLBCL-like NLPHL (pattern E) were reviewed to explore this challenging differential diagnosis and critically evaluate whether aggressive behavior and transformation of NLPHL can be predicted in practice.
Identifiants
pubmed: 37530790
doi: 10.1007/s00428-023-03554-1
pii: 10.1007/s00428-023-03554-1
pmc: PMC10611620
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
451-463Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : HA6145/7-1
Informations de copyright
© 2023. The Author(s).
Références
Am J Surg Pathol. 2004 Apr;28(4):489-95
pubmed: 15087668
Blood. 2000 Sep 1;96(5):1889-99
pubmed: 10961891
Blood. 2022 Sep 15;140(11):1229-1253
pubmed: 35653592
Hum Pathol. 2017 Oct;68:47-53
pubmed: 28851661
Haematologica. 2010 Mar;95(3):440-8
pubmed: 19797726
Am J Surg Pathol. 2008 Aug;32(8):1252-7
pubmed: 18594468
Haematologica. 2014 Apr;99(4):715-25
pubmed: 24510338
Blood. 2021 Mar 11;137(10):1353-1364
pubmed: 32871584
Br J Haematol. 2014 Oct;167(2):238-42
pubmed: 24965443
Leukemia. 2022 Jul;36(7):1720-1748
pubmed: 35732829
Mod Pathol. 2020 May;33(5):834-845
pubmed: 31822802
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
PLoS One. 2013 Nov 11;8(11):e78812
pubmed: 24244368
J Clin Oncol. 2008 Jan 20;26(3):434-9
pubmed: 18086799
Appl Immunohistochem Mol Morphol. 2019 Mar;27(3):180-184
pubmed: 28877074
Am J Surg Pathol. 2014 Mar;38(3):316-24
pubmed: 24525501
Virchows Arch B Cell Pathol Incl Mol Pathol. 1979;31(3):211-25
pubmed: 43015
Haematologica. 2019 Feb;104(2):330-337
pubmed: 30213827
Hum Pathol. 2022 Nov;129:32-39
pubmed: 35987347
Blood. 2018 Oct 4;132(14):1519-1525
pubmed: 30064977
Ann Oncol. 2006 Jan;17(1):141-5
pubmed: 16284059
Am J Surg Pathol. 2018 Mar;42(3):342-350
pubmed: 29309299
Mod Pathol. 2019 Jan;32(1):37-47
pubmed: 30140037
Haematologica. 2015 Dec;100(12):1579-86
pubmed: 26430172
Blood. 2013 Dec 19;122(26):4246-52; quiz 4292
pubmed: 24100447
Br J Haematol. 2015 May;169(3):415-22
pubmed: 25644177
Histopathology. 1979 Jul;3(4):295-308
pubmed: 468131
Am J Surg Pathol. 2003 Oct;27(10):1346-56
pubmed: 14508396
Int J Mol Sci. 2016 Dec 16;17(12):
pubmed: 27999289
Mod Pathol. 2022 Oct;35(10):1431-1438
pubmed: 35173297
Leukemia. 2016 Apr;30(4):844-53
pubmed: 26658840